Fengling Wang
Impact in
- Molecular Medicine top 5%
- Curcumin's Biomedical Applications
- Cancer Research top 5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Papers in ⓘ
-
- Curcumin's Biomedical Applications 5
- Oncology 24
- CAR-T cell therapy research 7
- Drug Transport and Resistance Mechanisms 7
- Co-authors
- Shaoping Ji (8 shared papers)Adil J. Nazarali (2 shared papers)Weidong Chen (13 shared papers)Liangzhi Xia (4 shared papers)Zhengwei Xie (4 shared papers)Weidong Chen (3 shared papers)Ling Li (3 shared papers)Yuan Huang (4 shared papers)
- Journals
- Drug Metabolism and Disposition (3 papers)Frontiers in Pharmacology (3 papers)Acta Pharmaceutica Sinica B (2 papers)Neoplasia (2 papers)Biomedicine & Pharmacotherapy (2 papers)
- Partner nations
- ChinaUnited StatesPakistan
In The Last Decade
Fengling Wang
121 papers receiving 2.1k citations
Peers
Comparison fields: 5 of 151
- Molecular Medicine 132
- Cancer Research 399
- Biomaterials 245
- Molecular Biology 891
- Immunology 212
Countries citing papers authored by Fengling Wang
This map shows the geographic impact of Fengling Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengling Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengling Wang more than expected).
Fields of papers citing papers by Fengling Wang
This network shows the impact of papers produced by Fengling Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengling Wang. The network helps show where Fengling Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Fengling Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 124 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Circular RNAs as potential biomarkers for cancer diagnosis and therapy. | 2016 | 225 |
| 2 | 2018 | 92 | |
| 3 | 2015 | 78 | |
| 4 | 2018 | 74 | |
| 5 | 2018 | 59 | |
| 6 | 2023 | 59 | |
| 7 | 2022 | 57 | |
| 8 | 2009 | 55 | |
| 9 | 2022 | 52 | |
| 10 | 2001 | 46 | |
| 11 | 2021 | 45 | |
| 12 | 2021 | 45 | |
| 13 | 2020 | 39 | |
| 14 | 2016 | 39 | |
| 15 | 2022 | 38 | |
| 16 | 2018 | 37 | |
| 17 | 2016 | 36 | |
| 18 | 2020 | 34 | |
| 19 | 2014 | 33 | |
| 20 | 2022 | 30 |
About Fengling Wang
Fengling Wang is a scholar working on Molecular Medicine, Oncology, Pharmacology, Cancer Research and Biomaterials, having authored 124 papers that have together received 2.2k indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (8 papers), Natural product bioactivities and synthesis (8 papers), CAR-T cell therapy research (7 papers), Drug Transport and Resistance Mechanisms (7 papers), RNA Interference and Gene Delivery (6 papers), Metal-Organic Frameworks: Synthesis and Applications (5 papers), RNA modifications and cancer (5 papers) and Curcumin's Biomedical Applications (5 papers). The work is most often cited by research in Molecular Medicine (132 citations), Cancer Research (399 citations), Biomaterials (245 citations), Molecular Biology (891 citations) and Immunology (212 citations). Fengling Wang has collaborated with scholars based in China, United States and Pakistan. Frequent co-authors include Shaoping Ji, Adil J. Nazarali, Weidong Chen, Liangzhi Xia, Zhengwei Xie, Weidong Chen, Ling Li, Yuan Huang, Lijia Li and Jingjing Yang. Their work appears in journals such as Drug Metabolism and Disposition, Frontiers in Pharmacology, Acta Pharmaceutica Sinica B, Neoplasia and Biomedicine & Pharmacotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.